Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)
Status:
Not yet recruiting
Trial end date:
2023-05-30
Target enrollment:
Participant gender:
Summary
There are currently no target therapies approved for treatment of anaplastic thyroid cancer
(ATC), leading to a clear need for improving therapy for ATC. This is a single-arm,
multicenter study to evaluate the efficacy and safety of HX008 injection in patients with
metastatic or locally advanced anaplastic thyroid cancer.